Medical/Pharmaceuticals
SK Biopharmaceuticals Names Donghoon Lee, Head of Bio Investment Center of SK Inc., as New CEO
Mr. Lee brings expertise in global new biz development to further strengthen SK Biopharmaceuticals as SK Group's key bio business PANGYO, South Korea, Nov. 30, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that it has named Mr. Donghoon Lee, Ex...
2022-12-01 09:30
2830
New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio
DUBLIN, Dec. 1, 2022 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to
announce a new license agreement withCosmo Bio. This is a non-exclusive license
agreement grantingJapan's Cosmo Bio access to the ERS CRISPR/Cas9 patent
portfolio.
2022-12-01 08:00
2285
Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne
--To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end ofFebruary 2023 -- Clinical efficacy observed in patients who have completed 12-week treatment of ASC40 or placebo was comparable t...
2022-11-30 20:39
2321
WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan
SHANGHAI, Nov. 29, 2022 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced that it is a r...
2022-11-30 08:00
3243
United Imaging Selected to Academy of Radiology & Biomedical Imaging Research's Council of Distinguished Investigators' Class of 2022
United Imaging's Chief Technology Officer recognized at a ceremony and reception during RSNA onTuesday, November 29, 2022. HOUSTON, Nov. 29, 2022 /PRNewswire/ -- United Imaging, a global leader in producing advanced medical imaging and radiotherapy equipment, is welcomed today to the Distinguis...
2022-11-29 22:00
3407
Yuyu Pharma Plans to Enter the U.S. and European Markets for Hair Loss Treatment
SEOUL, South Korea, Nov. 29, 2022 /PRNewswire/ -- At the World Congress for
Hair Research 2022 (Melbourne, Australia), Yuyu Pharma shared its plans to
conduct clinical trials in the U.S. andEurope for its Dutasteride Tablet
("DUT") for the treatment of Androgenetic Alopecia ("AGA").
2022-11-29 16:20
5238
AROA BIOSURGERY ANNOUNCES HALF YEAR RESULTS
AUCKLAND, New Zealand, Nov. 29, 2022 /PRNewswire/ -- Today New Zealand based soft-tissue regeneration company Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23. With fewer COVID-19 related disruptions, the Company has entered FY23 with momentum and delivere...
2022-11-29 13:24
4952
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
Acquisition accelerates Full-Life's transformation into clinical stage radiopharmaceutical company, leveraging its European-focused Radiotechnology and Development Platform BRUSSELS and WATCHUNG, N.J. and SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- Full-Life Technologies, a fully integrated global r...
2022-11-29 10:00
3410
Cambridge Cognition and Luca Healthcare Announce a Strategic Partnership and an Exclusive Licensing Agreement to Commercialize Cambridge Cognition's Suite of Cognitive Assessment Tools and Brain Health Products for the China Market
SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- Cambridge Cognition, a leading technology company, which develops and markets digital solutions to assess brain health, and Luca Healthcare,China's category leader in developing and commercializing clinically validated digital health solutions, today annou...
2022-11-29 10:00
2935
Comirnaty Bivalent Vaccine Arrives in Hong Kong SAR and Macau SAR and Will Soon Be Available to the Local Residents
SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- On November 26, 2022, Shanghai Fosun Pharma (Group) Co., Ltd.("Fosun Pharma", Stock Code: 600196.SH; 02196.HK) announced that the first batch of about 770,000 doses of the Comirnaty Original/Omicron BA.4/BA.5 bivalent vaccine (i.e. Comirnaty Original/Omicro...
2022-11-28 22:59
5160
SeekIn Receives CE-IVD Mark Approval for SeekInCure® Cancer Recurrence Monitoring Kit
First-of-its-kind blood-based pan-cancer recurrence monitoring test SHENZHEN, China, Nov. 28, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for SeekInCure® Cancer Recurrence Moni...
2022-11-28 21:00
4166
DetectedX Introduces ImageDx to Transform Image-Based Education at RSNA
Showcases Momentum with New Customers, New Subscriber Options and the Addition ofProfessor László Tabár to the Executive Team CHICAGO, Nov. 28, 2022 /PRNewswire/ -- Building on the successful U.S. launch at the SBI/ACR Breast Imaging Symposium, DetectedX, the leaders in intelligent interactive ...
2022-11-28 21:00
4021
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
NEW TAIPEI CITY, Taiwan, Nov. 28, 2022 /PRNewswire/ -- Medeologix, a Taiwan MedTech CDMO company announces its successful acquisition of three premier medical device manufacturing companies to form an integrated full function service group. The newly formed Medeologix family of companies, with a ...
2022-11-28 21:00
5365
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
SHANGHAI and NEW ORLEANS, Nov. 28, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the preliminary safety and efficacy data from the Phase I study of GFH009 monotherapy for treatment ...
2022-11-28 19:00
3435
Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients
* LVGN7409 is a next generation CD40 agonistic antibody; Nivolumab is a PD-1 checkpoint inhibitor; docetaxel is an anti-tubulin chemotherapy agent * Combination study to begin in 1st half 2023 SHANGHAI and SUZHOU, China, Nov. 27, 2022 /PRNewswire/ -- Lyvgen Biopharma, a leading innovative glob...
2022-11-28 07:00
2574
New study on deep learning technology for improving MRI image quality published in European Radiology
SwiftMR™, an AI-powered MRI reconstruction solution from AIRS Medical proved
its performance for enhancing the image quality of 3D high-resolution MRI
SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ -- A recent study published in
European Radiology
2022-11-25 23:00
13971
Neurophet, to participate in the Radiological Society of North America RSNA 2022
̵ Introducing 4 products at the booth including the main product Neurophet AQUA ̵ Conducting in-depth discussions jointly team members from R&D and cooperation with several global companies SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution comp...
2022-11-25 22:00
13037
Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm
* Polytaxel, a novel pain-free anticancer drug, may not require break periods * A new standard of care, more convenient than docetaxel, is suggested * Hyundai Bioscience to enter clinical trial on pancreatic cancer in Australia * Patient-centered chemotherapy to enable outpatients to live nor...
2022-11-25 21:00
13188
Concord Medical Schedules 2022 Annual Meeting of Shareholders
BEIJING, Nov. 25, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensi...
2022-11-25 19:30
12821
Peijia Medical Limited and inQB8 Medical Technologies, LLC report Successful First-in-Human implantation of MonarQ Transcatheter Tricuspid Valve Replacement System
SUZHOU, China, Nov. 25, 2022 /PRNewswire/ -- inQB8 Medical Technologies, LLC (inQB8), in Partnership with Peijia Medical Limited (Peijia, (9996.HK)), announced today that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve in a 75-year-old female suffering from severe torrentia...
2022-11-25 16:00
3474
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 273 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24